The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.
The world of cell therapy is expanding rapidly, with biotechnology companies uncovering new approaches and applying novel therapeutics to new targets seemingly daily. Although the speed of development means great things for diseases with high unmet needs, it can make for a steep learning curve for the many players in this space who are working hard to challenge how we treat some of the world’s most devastating diseases.
Bringing together experts in the fields of cell therapy discovery, translation, development, manufacturing, logistics, and market access, the upcoming 2021 CAR-TCR Summit, taking place virtually August 30-September 2, seeks to help educate and invigorate participants in this rapidly changing field.
The 4-day Summit, which features more than 150 faculty members, will include can’t-miss insights from leaders in the commercial, research, and regulatory worlds, including:
Organized by 5 tracks, the Summit kicks off with “Deep Dive Day,” which includes the CAR-TCR 101 Bootcamp program and the Regulatory Bootcamp. Days 2 and 3 of the Summit will include the keynote presentation by Carl June,MD, director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania, scientific abstracts and plenary presentations, networking and tech slam sessions, as well as an Industry Leader’s Fireside Chat and Next-Generation Fireside Chat. The final day of the Summit is dubbed “Focus Day,” with sessions centered around cell characterization and applications of CAR and TCR therapies beyond oncology.
Each track features tailored sessions that address key issues and developments, including:
Clinical Development Track
Early Phase Development Track
Market Access Track
To register for the virtual, interactive event, visit CAR-TCR-Summit.com and stay with GeneTherapyLive for more insights from leaders in cell therapy.